The Clinical Effect of Normal Diet and Absolute Diet on Post-polypectomy Patients: an Open-label, Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-75 patient with initial diagnosis of colorectal polyp by colonoscopy;
- The maximum size of polyp is more than 20mm;
- The patients underwent single ESD procedure for the polyp and agreed to participate this trial.
Exclusion Criteria:
- Uncontrollable hypertension or diabetes;
- Severe comorbidities such as cancer and organ failure etc;
- Patients who were pregnant;
- Patients had anticoagulants during perioperative period;
- Patients with poor compliance. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Absolute diet
|
Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours.
Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting.
Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.
|
|
Experimental: Normal diet
|
Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy.
Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative adverse event rate
Time Frame: 14-day after polypectomy
|
Postoperative AE includes PPB, post polypectomy electrocoagulation syndrome(PPES) and delayed perforation.
|
14-day after polypectomy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
length of stay
Time Frame: 14-day after polypectomy
|
calculated by subtracting day of admission from day of discharge.
|
14-day after polypectomy
|
|
hospitalization cost
Time Frame: 14-day after polypectomy
|
represent the hospital's costs of patients at the hospital
|
14-day after polypectomy
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- NFEC-2017-080
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.